Bio-Path Holdings, Inc.

NasdaqCM:BPTH Stock Report

Market Cap: US$4.6m

Bio-Path Holdings Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Peter Nielsen

Chief executive officer

US$827.1k

Total compensation

CEO salary percentage69.5%
CEO tenure18yrs
CEO ownership0.03%
Management average tenure18yrs
Board average tenure8.7yrs

Recent management updates

Recent updates

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Nov 05
We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Aug 16

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Jul 08
Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Mar 24
Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Aug 17
Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Mar 26
We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Will Bio-Path Holdings (NASDAQ:BPTH) Spend Its Cash Wisely?

Dec 11
Will Bio-Path Holdings (NASDAQ:BPTH) Spend Its Cash Wisely?

Dosing underway in Bio-Path's early-stage BP1002 study

Nov 19

Bio-Path EPS beats by $0.07

Nov 13

CEO Compensation Analysis

How has Peter Nielsen's remuneration changed compared to Bio-Path Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$11m

Jun 30 2024n/an/a

-US$12m

Mar 31 2024n/an/a

-US$14m

Dec 31 2023US$827kUS$575k

-US$16m

Sep 30 2023n/an/a

-US$17m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$16m

Dec 31 2022US$1mUS$555k

-US$14m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$11m

Dec 31 2021US$1mUS$530k

-US$10m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$1mUS$510k

-US$11m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$735kUS$490k

-US$9m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$672kUS$490k

-US$9m

Compensation vs Market: Peter's total compensation ($USD827.12K) is about average for companies of similar size in the US market ($USD641.95K).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.

CEO

Peter Nielsen (75 yo)

18yrs

Tenure

US$827,117

Compensation

Mr. Peter H. Nielsen, MBA, is a Co-Founded Bio-path Holdings, Inc. in 2007 and has been its Chairman, President, Chief Executive Officer, Chief Financial Officer and Treasurer since 2008. Mr. Nielsen licen...

Leadership Team

NamePositionTenureCompensationOwnership
Peter Nielsen
Co-Founder18yrsUS$827.12k0.030%
$ 1.4k
Douglas Morris
Co-Founder18yrsUS$89.98k0%
$ 0
Michael Hickey
VP of Clinical Operations2yrsno datano data
Anthony Price
Senior Vice President of Financeno datano datano data
Ana Ashizawa
Senior Vice President of Researchno datano datano data

18.0yrs

Average Tenure

Experienced Management: BPTH's management team is seasoned and experienced (18 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peter Nielsen
Co-Founder17yrsUS$827.12k0.030%
$ 1.4k
Douglas Morris
Co-Founder18yrsUS$89.98k0%
$ 0
Jorge Cortes
Chairman of the Scientific Advisory Board9.4yrsno datano data
Paul Aubert
Independent Director6.9yrsUS$73.81k0%
$ 0
Jason Fleming
Member of the Scientific Advisory Board6.4yrsno datano data
Heath Cleaver
Independent Director10.9yrsUS$85.31k0%
$ 0
D. Hooper
Member of the Scientific Advisory Board7.9yrsno datano data
Aline Sherwood
Independent Director2.8yrsUS$76.81k0%
$ 0

8.7yrs

Average Tenure

54yo

Average Age

Experienced Board: BPTH's board of directors are considered experienced (8.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 05:12
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bio-Path Holdings, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertMaxim Group
Pamela BassettMaxim Group
Raghuram SelvarajuRodman & Renshaw, LLC